trial · primary record
Firmonertinib 80mg qd oral for 8 weeks.
NSCLC
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2029-12-30 |
| Primary endpoint | Major Pathological Response (MPR) Rate |
| Registry ID | NCT07622706 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:37.684Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07622706
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.